Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 286
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02709109 | A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation | ||
| NCT06345755 | A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants | ||
| NCT03447262 | A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy | ||
| NCT04599465 | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) | ||
| NCT05661734 | A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain | ||
| NCT01048255 | Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy | ||
| NCT07010406 | A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations | ||
| NCT01807949 | A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation | ||
| NCT02392234 | A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation | ||
| NCT01897233 | Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT05727800 | A Phase 1, First-in-human Study of VX-668 | ||
| NCT06834009 | A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists | ||
| NCT02343445 | Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF) | ||
| NCT06887972 | A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries | ||
| NCT03764072 | A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | ||
| NCT01754935 | A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor | ||
| NCT04235140 | Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation | ||
| NCT00758043 | A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response | ||
| NCT04208529 | A Long-term Follow-up Study in Participants Who Received CTX001 | ||
| NCT02871778 | Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia | ||
| NCT03277196 | A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation | ||
| NCT01381289 | VX-770 Expanded Access Program | ||
| NCT01216046 | Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects | ||
| NCT06696443 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | ||
| NCT03125395 | A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT05955872 | A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 | ||
| NCT06886269 | A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose | ||
| NCT06508762 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 | ||
| NCT00973388 | VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers | ||
| NCT05444257 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | ||
| NCT03061331 | Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation | ||
| NCT01161537 | Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation | ||
| NCT07378865 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants | ||
| NCT03068312 | A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation | ||
| NCT00500812 | A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries | ||
| NCT02412111 | A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor | ||
| NCT00205465 | Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 | ||
| NCT07584434 | A Phase 1, First-in-human Study of VX-433 | ||
| NCT00389298 | A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. | ||
| NCT04537793 | Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years | ||
| NCT02953314 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) | ||
| NCT06820307 | Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants | ||
| NCT05867147 | An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants | ||
| NCT05477563 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | ||
| NCT02951182 | A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis | ||
| NCT06861413 | A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation | ||
| NCT02514473 | A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation | ||
| NCT04474197 | Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype | ||
| NCT06154447 | Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis | ||
| NCT05558410 | Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty |
